Quitting After Cancer Diagnosis: Misconception vs. Survival Reality

Stopping smoking after a cancer diagnosis can significantly improve survival rates and reduce the risk of disease progression, according to the eighth evidence synthesis report issued by the International Agency for Research on Cancer (IARC). The findings are being presented on September 25, 2026, at the Union for International Cancer Control (UICC) World Cancer Congress in Hong Kong. While the benefits of quitting to prevent cancer are well established, a persistent misconception remains that quitting after a diagnosis offers no further benefit. According to IARC, data gathered over the past decade demonstrates that smoking cessation following a diagnosis is associated with improved survival outcomes.

Lung Cancer Survival Rates Following Smoking Cessation

Among them, 220 patients—representing 42 percent—quit smoking during the follow-up period, with 80 percent doing so within the first three months. Patients who quit smoking lived an average of 22 months longer than those who continued. Five years after diagnosis, overall survival reached 60.6 percent for those who quit, compared to 48.6 percent for continuing smokers. Progression-free survival stood at 54.4 percent versus 43.8 percent. After adjusting for various factors, quitting smoking was associated with a 33 percent reduction in all-cause mortality, a 25 percent reduction in cancer-specific mortality, and a 30 percent reduction in disease progression risk.

Kidney Cancer Outcomes After Quitting

A second study examined 212 patients diagnosed with renal cell carcinoma who smoked at diagnosis, tracking them for an average of eight years. During this period, 84 individuals—or 40 percent—stopped smoking, largely within the first three months after diagnosis. At three years, mortality rates were 6 percent for those who quit compared to 24 percent for those who continued. At five years, those rates were 15 percent and 40 percent respectively. After adjusting for patient, cancer, and treatment characteristics, quitting smoking was linked to a 50 percent decrease in all-cause mortality, a 46 percent decrease in cancer-related mortality, and a 55 percent decrease in disease progression risk relative to continuing smokers. These survival benefits appeared across all cancer stages, including stage IV patients.

Smoking Cessation Support in Cancer Care Is Cost-Effective

Beyond clinical outcomes, IARC highlighted the economic viability of embedding smoking cessation support directly into cancer care pathways. An analysis from the perspective of the British National Health Service (NHS) evaluated the cost-effectiveness of offering cessation support right at the time of a cancer diagnosis. The additional costs required to gain a quality-adjusted life year (QALY) ranged from 2,606 British pounds (approximately 3,030 euros) for lung cancer to 5,495 pounds (6,390 euros) for head and neck cancers. These figures sit well below the standard 20,000-pound (23,000-euro) per QALY threshold typically used to determine acceptable intervention cost-effectiveness. Direct integration into care pathways yielded a net monetary benefit compared to outside referrals, estimated at 1,543 pounds (1,794 euros) per lung cancer patient and 5,362 pounds (6,235 euros) per kidney cancer patient.